| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 苏州昊帆生物股份有限公司，成立于2003年，总部坐落于苏州市高新区，是一家为全球医药研发及原料药生产企业提供特色原料的高新技术企业。我们的产品主要应用于多肽、核苷酸和医药合成等领域，产品范围涵盖特色酰胺键构成用多肽合成试剂、分子砌块、蛋白质试剂、脂质体与脂质纳米粒药用试剂、离子液体、PROTAC试剂和核苷酸试剂等种类。目前已累计研发生产各类产品达1500多种。 多年来昊帆生物坚持“不断创新、客户满意”的原则，致力于服务新药研发的前端进程，为创新药物研发和药品生产提供快速、精准的配套服务。通过紧跟全球创新药研发方向，贴近国内外CRO、CDMO公司的市场需求，已成为业内领先的特色功能化学品供应商。 | ||||||||||||||||||||||||
| Main Business | 从事多肽合成试剂、通用型分子砌块、蛋白质试剂等产品的研发、生产与销售。 | ||||||||||||||||||||||||
| Legal Representative | 朱勇 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 董胜军 | ||||||||||||||||||||||||
| Solicitors | 上海市广发律师事务所 | ||||||||||||||||||||||||
| Auditors | 中天运会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0512-65399366 | ||||||||||||||||||||||||
| Fax No | 0512-68056883 | ||||||||||||||||||||||||
| Website | www.highfine.com | ||||||||||||||||||||||||
| ir@highfine.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 12/07/2023 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 1.250 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.390 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 21.002 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 1.942B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |